The value of temperature-sensitive liquid embolic agents in interventional embolization of arteriovenous malformations in children

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400089506

Enrollment

Unknown

Registered

2024-09-10

Start date

2024-09-20

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arteriovenous malformations

Interventions

The experimental group:Using temperature sensitive liquid embolic agents

Eligibility

Sex/Gender

All

Age

1 Years to 18 Years

Inclusion criteria

Inclusion criteria: ? Age 1-18 years old; ? AVMs was diagnosed by clinical evaluation, Doppler vascular ultrasound, computed tomography angiography or magnetic resonance imaging before operation; ? AVMs confirmed by DSA; ? The patient's family members signed the written informed consent; ? patients were willing to accept clinical follow-up; ? The following laboratory indicators should be met: absolute neutrophil count (ANC) =1.5x109/L; Platelet count =90×109/L; Hemoglobin =9g/dL; Total bilirubin =2.0× upper limit of normal value (ULN); Albumin =2.8g/dL; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =5×ULN; Serum creatinine =1.5×ULN and creatinine clearance (calculated by Cockcroft-Gault formula) =30ml/min; Good coagulation function was defined as international normalized ratio (INR) or prothrombin time (PT) =1.5 times ULN.

Exclusion criteria

Exclusion criteria: ? Contrast agent, embolic agent and heparin allergy; ? Intracranial AVMs; ? other types of vascular malformations such as arterial malformation, venous malformation and venous lymphatic malformation; ? symptomatic congestive heart failure (New York Heart Association class III-IV); 5. Unable to control high blood pressure; 6 a history of human immunodeficiency virus (HIV) infection; ? Systemic or local infection in active stage or poorly controlled clinical; (8) History of immune vascular disease, tumor, or suspected blood-rich manifestations of tumor.

Design outcomes

Primary

Measure	Time frame
Improvement of postoperative clinical symptoms;Rate of tumor nests to de vascularization;Rate of recurrence;Incidence of complications;Survival rates;	—

Secondary

Measure	Time frame
Technical success rate;Length of stay;Cost of treatment;Rate of rehospitalization;	—

Countries

China

Contacts

Public ContactYunpei Chen

Fujian Children's Hospital

ccyp110@163.com+86 173 2201 1215

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026